Daré Bioscience(DARE) - 2025 Q3 - Quarterly Results

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim DSMB Outcome for Ovaprene Phase 3 Study Supports Continued Enrollment Exhibit 99.1 Multiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting as well as Non-Hormonal Contraception Four Commercially Available Solutions for Women Expected Over the Next Tw ...